Penicillamine Tablets USP 250 mg — Class II drug recall D-0148-2024
Terminated recall by Lupin Pharmaceuticals Inc., reported 2023-12-20. Failed Dissolution Specifications
| Recall number | D-0148-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2023-11-22 |
| Classified | 2023-12-13 |
| Reported by FDA | 2023-12-20 |
| Terminated | 2024-07-08 |
| Reason classes | specification failure |
| NDC | 70748-0153, 70748-0153-01 |
| Lot numbers | M200498 |
| Expiration dates | 2024-06-20 |
Product
Penicillamine Tablets USP 250 mg, 100-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 Manufactured by: Lupin Limited, Nagpur-441 108, India, NDC# 70748-153-01
Reason for recall
Failed Dissolution Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0148-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.